Macrophage Migration Inhibitory Factor for Diagnosing Endometriosis and Its Severity
1 other identifier
observational
300
0 countries
N/A
Brief Summary
Endometriosis is a chronic disease affecting women of reproductive age. Macrophage migration inhibitory factor (MIF) is one of non-invasive blood biomarker that was detected in sera of endometriotic patients.The aim of this study was to evaluate the value of serum macrophage migration inhibitory factor in diagnosing endometriosis in women with infertility and chronic pelvic pain and correlate its level with the stage of the disease. Three hundred patient candidate for diagnostic laparoscopy were included in a case-control observational study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2016
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2018
CompletedFirst Submitted
Initial submission to the registry
September 13, 2019
CompletedFirst Posted
Study publicly available on registry
September 17, 2019
CompletedSeptember 19, 2019
September 1, 2019
1.5 years
September 13, 2019
September 17, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
level of serum macrophage migration inhibitory factor and stage of the disease
serum MIF is a promising marker for noninvasive diagnosis of severity of endometriosis
one year
Study Arms (2)
endometriosis
laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
control
diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
Interventions
laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
Eligibility Criteria
Both groups were comparable regarding the baseline characteristics. these included age, parity, Body mass index, symptoms, type of infertility and chronic pelvic pain
You may qualify if:
- postmenstrual women
- in childbearing period,
- presenting with either gynecologic chronic pelvic pain (CPP) or infertility
- indicated and fit for diagnostic laparoscopy.
- All women must have no hormonal treatment for the last 3 months and.
You may not qualify if:
- Women with bleeding tendency,
- suspicious of gynecologic malignancy or
- active infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate Professor
Study Record Dates
First Submitted
September 13, 2019
First Posted
September 17, 2019
Study Start
March 1, 2016
Primary Completion
September 1, 2017
Study Completion
September 1, 2018
Last Updated
September 19, 2019
Record last verified: 2019-09